CN106492110B

CN106492110B - Hangover alleviating composition, hangover alleviating and liver protecting preparation containing same and application of hangover alleviating and liver protecting preparation

Info

Publication number: CN106492110B
Application number: CN201610980881.7A
Authority: CN
Inventors: 赵兵; 赵庆生; 王强
Original assignee: Beijing Zhongke Joinyou Biotechnology Co ltd; Institute of Process Engineering of CAS
Current assignee: Beijing Zhongke Joinyou Biotechnology Co ltd; Institute of Process Engineering of CAS
Priority date: 2016-11-08
Filing date: 2016-11-08
Publication date: 2020-08-04
Anticipated expiration: 2036-11-08
Also published as: CN106492110A

Abstract

The invention provides an anti-inebriation composition, an anti-inebriation liver-protecting preparation containing the same and application of the anti-inebriation liver-protecting preparation, wherein the anti-inebriation composition comprises the following components: maca extract, kudzu root extract, turmeric extract and hovenia dulcis thunb extract. The hangover alleviating composition disclosed by the invention is scientifically and reasonably compounded by selecting specific raw materials, can promote rapid absorption and decomposition of alcohol in a body, is beneficial to rapid hangover alleviation of an alcohol taker, prevents hangover, and has a good liver protection effect. The anti-alcohol composition can be prepared into an anti-alcohol and liver-protecting preparation or applied to liver-protecting functional food.

Description

Hangover alleviating composition, hangover alleviating and liver protecting preparation containing same and application of hangover alleviating and liver protecting preparation

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and relates to an anti-inebriation composition, an anti-inebriation liver-protecting preparation containing the same and application thereof.

Background

The liver is the central hub of carbohydrate metabolism, lipid metabolism and protein metabolism of human body and has important functions of expelling toxin, detoxifying, secreting bile and the like. After drinking, alcohol is absorbed mainly through the stomach (20%) and duodenum (80%), and about 90% of alcohol is metabolized in the liver. Alcohol has cytotoxicity, and can overoxidize lipid on the surface of liver cell membrane, destroy liver cell membrane, further develop and destroy the microtubule and mitochondria in liver cell, and cause metabolism disorder in cell, and result in the generation of cytotoxic metabolite, thereby causing liver cell swelling and necrosis. Nowadays, under the influence of wine table culture, many people drink too much wine to exceed the limit of alcohol metabolism of human bodies, so that the damage of livers and the decline of liver functions are caused, and the health of the human bodies is greatly threatened.

Western medicines have good effects in a short time, but cannot perform systemic treatment and recuperation on human bodies, and have great side effects. The essence of the health-care functional food is food, which contains a certain amount of functional components, can regulate the functions of human bodies, maintain health or prevent certain diseases, is safe and non-toxic, and is wide in beneficial people; with the gradual enhancement of health and safety awareness of consumers, the health care product has wide market prospect.

CN101716001A discloses a beverage for alleviating hangover and protecting liver and a production method thereof, wherein the beverage comprises the following raw materials by weight: the raw materials comprise 15% of kudzuvine root, 10% of oriental wormwood, 10% of kudzuvine flower, 10% of momordica grosvenori, 10% of tamarind fruit, 10% of long-pending shell, 10% of long-pending chessman, 10% of liquorice, 15% of dried orange peel, 5% of pectin and 3% of mint, and the raw materials are cleaned, crushed, soaked, heated, filtered, clarified, seasoned, flavored, filtered with glue, sterilized and filled to; has effects in promoting bile flow, protecting liver, promoting urination, inhibiting gastrointestinal absorption, and relieving alcoholism.

CN101972462A discloses an anti-alcohol health care product for relieving alcohol and eliminating dampness, tonifying qi and strengthening spleen, and promoting qi circulation and diuresis, which is prepared from the following medicinal plants in part by weight: 20-60 parts of semen hoveniae, 20-50 parts of pueraria flower (or kudzuvine root), 10-30 parts of chrysanthemum, 5-20 parts of cogongrass rhizome, 5-20 parts of phaseolus calcaratus, 5-10 parts of dark plum, 5-10 parts of dried ginger, 5-20 parts of hawthorn and 5-20 parts of fried malt; can also be added with: 5-10 parts of bighead atractylodes rhizome; the formula regulates the functions of viscera and has rapid anti-alcoholism effect and obvious effect by compatibility of medicines and comprehensive application of methods of promoting qi circulation, inducing diuresis, tonifying deficiency, harmonizing stomach, activating spleen and the like.

In the field, the Chinese medicinal composition has a good application prospect in the development of Chinese medicinal anti-inebriation medicaments, and more safe and effective Chinese medicinal compositions with protection and adjuvant therapy effects on alcoholic liver injury are expected to be obtained.

Disclosure of Invention

Aiming at the defects of the prior art, the invention aims to provide an anti-inebriation composition, an anti-inebriation liver-protecting preparation containing the same and application thereof. The anti-alcohol composition has a protection function and an auxiliary treatment effect on alcoholic liver injury, and has a good pharmacological effect.

In order to achieve the purpose, the invention adopts the following technical scheme:

in one aspect, the invention provides an anti-hangover composition, which comprises the following raw material extract components: maca extract, kudzu root extract, turmeric extract and hovenia dulcis thunb extract.

The anti-alcoholism composition disclosed by the invention has the effects of protecting and treating alcoholic liver injury by mutually matching the basic raw materials of the herbaceous plants such as the maca extract, the kudzu root extract, the turmeric extract and the hovenia dulcis thunb extract, and solves the problem of increasing of people with liver injury caused by drinking.

According to the invention, the maca extract, the kudzu root extract, the turmeric extract and the hovenia dulcis thunb extract are scientifically and reasonably compounded, and the components are matched with each other within the dosage range, so that the effects of relieving alcoholism and protecting liver can be exerted, and any one or two components are lacked, or the effects of relieving alcoholism and protecting liver can be influenced if the dosage range of one or some components is changed.

Preferably, the anti-hangover composition comprises the following raw material extract components in parts by weight:

in the hangover alleviating composition of the present invention, the amount of the maca extract may be 1 part, 3 parts, 5 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts, or 25 parts.

In the anti-hangover composition of the present invention, the amount of the pueraria extract may be 1 part, 3 parts, 5 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts or 20 parts.

In the hangover alleviating composition of the present invention, the amount of the turmeric extract may be 0.3 parts, 0.6 parts, 1 part, 3 parts, 5 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts, or 25 parts.

In the anti-hangover composition of the present invention, the hovenia dulcis thunb extract may be used in an amount of 0.5 parts, 0.8 parts, 1 part, 3 parts, 5 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts or 25 parts.

further preferably, the anti-hangover composition comprises the following raw material extract components in parts by weight:

in the invention, the anti-hangover composition further comprises any one or a combination of at least two of dried orange peel extract, cistanche extract, wolfberry fruit extract, Chinese yam extract, hawthorn extract, Chinese date extract, licorice extract or poria cocos extract. The composition can be a combination of a dried orange peel extract and a cistanche salsa extract, a combination of a dried orange peel extract and a wolfberry fruit extract, a combination of a dried orange peel extract and a Chinese yam extract, a combination of a dried orange peel extract and a hawthorn extract, a jujube extract and a licorice extract, a combination of a licorice extract and a poria cocos extract, a combination of a cistanche salsa extract and a wolfberry fruit extract and a Chinese yam extract, and a combination of a dried orange peel extract and a wolfberry fruit extract, a Chinese yam extract, a hawthorn extract, a jujube extract, a licorice root extract and a poria cocos extract.

Preferably, the anti-hangover composition further comprises 1 to 7 parts by weight (e.g., 1 part by weight, 1.5 parts by weight, 2 parts by weight, 3 parts by weight, 4 parts by weight, 5 parts by weight, 6 parts by weight, or 7 parts by weight) of a citrus peel extract.

Preferably, the anti-hangover composition comprises 1 to 8 parts by weight (e.g., 1 part by weight, 2 parts by weight, 3 parts by weight, 4 parts by weight, 5 parts by weight, 6 parts by weight, 7 parts by weight, or 8 parts by weight) of cistanche deserticola extract.

Preferably, the anti-hangover composition further comprises 1 to 6 parts by weight (e.g., 1 part by weight, 2 parts by weight, 3 parts by weight, 4 parts by weight, 5 parts by weight, or 6 parts by weight) of the extract of lycium barbarum.

Preferably, the anti-hangover composition further comprises 1 to 5 parts by weight (e.g., 1 part by weight, 2 parts by weight, 3 parts by weight, 4 parts by weight, or 5 parts by weight) of yam extract.

Preferably, the anti-hangover composition further comprises 1 to 7 parts by weight (e.g., 1 part by weight, 2 parts by weight, 3 parts by weight, 4 parts by weight, 5 parts by weight, 6 parts by weight, or 7 parts by weight) of the hawthorn extract.

Preferably, the anti-hangover composition further comprises 1 to 3 parts by weight (e.g., 1 part by weight, 1.3 parts by weight, 1.5 parts by weight, 1.8 parts by weight, 2 parts by weight, 2.5 parts by weight, 2.8 parts by weight, or 3 parts by weight) of a jujube extract.

Preferably, the anti-hangover composition further comprises 1 to 3 parts by weight (e.g., 1 part by weight, 1.3 parts by weight, 1.5 parts by weight, 1.8 parts by weight, 2 parts by weight, 2.5 parts by weight, 2.8 parts by weight, or 3 parts by weight) of a licorice extract.

Preferably, the anti-hangover composition further comprises 1 to 5 parts by weight (e.g., 1 part by weight, 2 parts by weight, 3 parts by weight, 4 parts by weight, or 5 parts by weight) of a poria cocos extract.

A typical but non-limiting example is: the anti-alcohol composition comprises the following raw material extract components in parts by weight:

another typical but non-limiting example is: the anti-alcohol composition comprises the following raw material extract components in parts by weight:

the anti-alcoholism composition is prepared by mixing the components of the raw material extracts.

The above-mentioned raw material extract components can be obtained by separately extracting the respective raw materials to obtain the respective extract components as described above. The raw materials corresponding to the components can be mixed for extraction, and the dosage of the raw materials can be adjusted according to the formula proportion of the desired anti-inebriation composition to obtain the expected anti-inebriation composition.

Preferably, the mixing and extracting process comprises mixing and crushing the raw materials, soaking in water for 1-2h (such as 1h, 1.2h, 1.4h, 1.6h, 1.8h or 2h), extracting, and concentrating under reduced pressure in vacuum to obtain concentrated solution with density of 1.02-1.06g/m L (such as 1.02g/m L, 1.03g/m L, 1.04g/m L, 1.05g/m L or 1.06g/m L) to obtain the hangover alleviating composition;

preferably, the mixing and extracting process comprises mixing and crushing the raw materials, soaking for 1-2h (such as 1h, 1.2h, 1.4h, 1.6h, 1.8h or 2h), performing ultrasonic circulation extraction, and concentrating under vacuum and reduced pressure until the density is 1.02-1.06g/m L (such as 1.02g/m L, 1.03g/m L, 1.04g/m L, 1.05g/m L or 1.06g/m L) to obtain a concentrated solution, thereby obtaining the hangover-alleviating composition;

preferably, the ultrasonic power for the ultrasonic circulation extraction is 300-2000W (such as 300W, 350W, 400W, 450W, 500W, 600W, 700W, 800W, 900W, 1000W, 1200W, 1500W, 1800W or 2000W), and the extraction temperature is 20-30 ℃ (such as 20 ℃, 22 ℃, 24 ℃, 26 ℃, 28 ℃ or 30 ℃).

On the other hand, the invention provides an anti-alcoholism and liver-protecting preparation, which comprises the anti-alcoholism composition.

Preferably, the preparation for alleviating hangover and protecting liver can be in the form of capsules, tablets, pills, oral liquid, ointment, gel or aerosol.

In the invention, the anti-alcoholism composition (i.e. the concentrated solution prepared as above) can be directly prepared into oral liquid, ointment, gel or aerosol.

Preferably, the anti-hangover composition (i.e., the concentrated solution prepared above) is dried to powder and then prepared into capsules, tablets or pills. Preferably, the drying is by spray drying.

Preferably, the capsule is a soft capsule. The shape of the soft capsule is oval, round, spherical or drop shape, preferably oval. In the preparation for relieving alcoholism and protecting liver, the soft capsule can overcome the defects of the tablet, and after the traditional tablet is swallowed by a person, the medicinal ingredients are disintegrated, dissolved, sucked and the like, so that the time is longer, and the medicinal effect loss is higher; and at the same time, moisture absorption and deterioration of the components are easily caused. The soft capsule preparation can be directly absorbed in intestinal tract after disintegration, does not need to be dissolved, and effectively avoids acid erosion of gastric acid and digestion and absorption of gastric wall, so that the soft capsule preparation has the excellent characteristics of accurate content, high bioavailability, good pharmacological effect, good stability of functional substances, good sealability, covering the unpleasant odor of the medicine, convenient administration and the like.

In the invention, the preparation method of the soft capsule comprises the following steps:

(1) weighing the components according to the formula, and mixing to obtain a component mixture;

(2) and (3) carrying out the steps of preparing materials, pelleting, shaping, drying, checking pills, packaging, checking and externally packaging on the component mixture, and filling the soft capsules to obtain the soft capsules.

On the other hand, the invention provides the application of the hangover alleviating composition in functional foods for protecting liver. The anti-alcoholism composition can be used in functional food for protecting liver with a proper dosage so as to play a health-care role on human body.

Compared with the prior art, the invention has the following beneficial effects:

the hangover alleviating composition is prepared by selecting specific raw materials, scientifically and reasonably compounding, and animal experiments and human body feeding tests prove that the product can promote the rapid absorption and decomposition of alcohol in vivo, is beneficial to the rapid hangover alleviation of alcohol pickers, prevents hangover and has a good liver protection effect.

Drawings

FIG. 1 is a graph showing the change in body weight of mice of each treatment group in example 10;

FIG. 2 is a graph showing the results of the change in the liver organ coefficient of each treated group of mice measured in example 10.

FIG. 3 is a graph showing the results of the serum A L T level of mice of each treatment group measured in example 10;

FIG. 4 is a graph showing the results of serum AST levels of mice of each treatment group measured in example 10;

FIG. 5 is a graph showing the results of serum TG levels in mice of each treatment group measured in example 10;

FIG. 6 is a graph showing the results of measuring the serum L D L-c level of each treated group of mice in example 10;

FIG. 7 is a graph showing the results of serum CHO levels of mice of each treatment group measured in example 10;

FIG. 8 is a graph showing the results of the serum gamma-GT levels of mice in each treatment group measured in example 10;

FIG. 9 is a graph showing the results of measuring the level of TBI L in the serum of mice in each treatment group in example 10;

FIG. 10 is a graph showing the results of serum ACP levels in mice of each treatment group measured in example 10;

FIG. 11 is a graph showing the results of measuring hepatic TG levels of mice of each treatment group in example 10;

FIG. 12 is a graph showing the results of measuring hepatic SOD levels of mice of each treatment group in example 10;

FIG. 13 is a graph of the results of liver MDA levels determined in example 10 for mice from each treatment group;

FIG. 14 is a graph showing the results of the GST levels in the liver of mice in each treatment group determined in example 10;

FIG. 15 is a graph showing the results of liver GSHPX levels of mice of each treatment group measured in example 10;

FIG. 16 is a graph showing the results of the liver GSH levels of mice of each treatment group determined in example 10;

FIG. 17 is a graph showing the results of liver CAT levels of mice of each treatment group measured in example 10;

FIG. 18 is a graph showing the results of liver L DH levels of mice of each treatment group measured in example 10.

Detailed Description

The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.

Example 1

In this embodiment, the hangover alleviating composition is composed of the following components in parts by weight:

1 part of maca extract, 3 parts of kudzu root extract, 5 parts of turmeric extract and 2 parts of hovenia dulcis thunb extract.

The preparation method comprises the following steps: the anti-alcoholism composition is prepared by respectively extracting maca, kudzu root, turmeric and hovenia dulcis thunb to obtain the extracts, and then mixing the above components according to the formula amount.

The anti-alcoholism composition is subjected to the steps of preparing materials, pelleting, shaping, drying, checking pills, packaging, checking and externally packaging to be encapsulated, so as to obtain the soft capsule.

Example 2

5 parts of maca extract, 4 parts of kudzu root extract, 1 part of turmeric extract and 4 parts of hovenia dulcis thunb extract.

Example 3

10 parts of maca extract, 2 parts of kudzu root extract, 8 parts of turmeric extract and 6 parts of hovenia dulcis thunb extract.

Example 4

20 parts of maca extract, 8 parts of kudzu root extract, 10 parts of turmeric extract and 10 parts of hovenia dulcis thunb extract.

Example 5

25 parts of maca extract, 1 part of kudzu root extract, 5 parts of turmeric extract and 20 parts of hovenia dulcis thunb extract.

Example 6

3 parts of maca extract, 2 parts of kudzu root extract, 2 parts of turmeric extract, 1 part of hovenia dulcis thunb extract and 1 part of cistanche deserticola extract.

The preparation method comprises the following steps: the anti-alcoholism composition is prepared by respectively extracting maca, kudzu root, turmeric, hovenia dulcis thunb and cistanche deserticola to obtain the extracts, and then mixing the above components according to the formula amount.

Example 7

4 parts of maca extract, 3 parts of kudzu root extract, 1 part of turmeric extract, 2 parts of hovenia dulcis thunb extract, 2 parts of dried orange peel extract and 2 parts of cistanche deserticola extract.

The preparation method comprises the steps of mixing the raw materials corresponding to the components, extracting, namely mixing and crushing the raw materials (namely maca, kudzu root, turmeric, hovenia dulcis thunb, dried orange peel and cistanche) of each component in the anti-alcoholism composition, soaking in water for 2 hours, extracting, concentrating under vacuum and reduced pressure to obtain concentrated solution with the density of 1.02g/m L after extraction is finished, spray-drying the concentrated solution to obtain powder, and carrying out capsule filling through the steps of proportioning, pelleting, shaping, drying, pill inspection, packaging, inspection and outer packaging to obtain the soft capsule.

Example 8

3 parts of maca extract, 2 parts of kudzu root extract, 2 parts of turmeric extract, 4 parts of hovenia dulcis thunb extract, 4 parts of liquorice extract, 1 part of poria cocos extract and 3 parts of wolfberry fruit extract.

The preparation method comprises mixing and pulverizing the raw materials of each component in the hangover alleviating composition, soaking for 2h, performing ultrasonic circulation extraction under the ultrasonic extraction condition of ultrasonic power 1000W and temperature 25 deg.C for 1.5h, vacuum concentrating under reduced pressure until the density is 1.04g/m L to obtain concentrated solution, spray drying the concentrated solution to obtain powder, and encapsulating through the steps of compounding, pelleting, shaping, drying, inspecting, packaging and external packaging to obtain the soft capsule.

Example 9

1 part of maca extract, 4 parts of kudzu root extract, 1 part of turmeric extract, 2 parts of hovenia dulcis thunb extract, 3 parts of liquorice extract, 3 parts of poria cocos extract, 2 parts of wolfberry fruit extract, 1 part of Chinese yam extract, 1 part of hawthorn extract, 1 part of Chinese date extract and 1 part of dried orange peel extract.

The preparation method comprises the following steps: the anti-alcoholism composition is prepared by respectively extracting maca, radix puerariae, turmeric, hovenia dulcis thunb, liquorice, poria cocos, wolfberry fruits, Chinese yams, hawthorn, Chinese dates and dried orange peels to obtain the extracts, and then mixing the above components according to the formula amount.

Example 10

In this embodiment, the liver protection effect of the anti-hangover composition prepared in example 1 on an alcoholic liver injury mouse is considered, and the specific experimental process is as follows:

an alcoholic liver injury mouse model is established by an ICR mouse with ethanol gavage, and the anti-inebriation composition preparation (test sample E) prepared in the example 1 is gavage at the same time, so that the liver protection effect of the test sample in the alcoholic liver injury mouse model is examined. After the experiment is finished, the mice are sacrificed, hematology and liver tissue biochemical and enzymology indexes are measured, and the action mechanism of the tested sample is preliminarily discussed.

Experimental materials: 60 ICR mice are female, the weight of the ICR mice is 22-25g, the ICR mice are bred in an SPF-level animal room, the animal room is illuminated for 12 hours and is alternately dark and bright, the temperature is 22-26 ℃, and the humidity is 40-60%. Mice were housed in IVC cages of 5 mice per cage and were fed free water during the experiment. The official experiment was started one week after the mice were purchased and acclimatized in the animal house. The operation and treatment of the experimental animal comply with the requirements of ethical examination guidelines of the experimental animal.

The experimental method comprises the steps of establishing an alcoholic liver injury mouse model, namely, after adaptively feeding female ICR mice of 6-8 weeks for one week, randomly grouping the mice into 6 groups according to the weight, wherein each group comprises 10 normal control groups, a model control group, positive medicine bicycloalkanol groups and three high, medium and low dose groups of a tested sample E, wherein the three dose groups comprise a normal control group, a model control group, a positive medicine bicycloalkanol group and a high, medium and low dose group of the tested sample E, the mice are subjected to 56 DEG G-Erguotou liquor and gavage for 31 days every day from the first day of the experiment, the ethanol dose in the Erguo liquor is increased along with the time, the specific scheme is that the ethanol is 2g/kg × 3 days, 4g/kg × 4 days and 6g/kg × 24 days, the mice of the normal control group are not subjected to gavage with the Erguo liquor in the experimental process.

The method comprises the steps of establishing an alcoholic liver injury mouse model (enema Erguotou wine) at 9 am of the day, and giving a test sample (the hangover alleviating composition preparation prepared in example 1) to an enema mouse, wherein mice of a normal control group and a model control group are subjected to stomach irrigation with distilled water, the doses of the positive control group and the positive control group are 300mg/kg, the doses of the test sample are three high, medium and low doses, the doses are respectively 200mg/kg, 600mg/kg and 1800mg/kg, and the volume of the stomach irrigation of all the mice is 10m L/kg.

The general state of the mouse is observed every day in the experimental process, if abnormal conditions such as listlessness, arch back, hair erection, obvious weight reduction and death occur, the general state is recorded in time, 4 hours after the last gastric lavage of the second pan head wine (administration day 31), the blood is taken from the orbit of the mouse, serum is separated, A L T, AST, ACP, GGT, TBI L, TG, CHO and L D L-c are measured according to the method of a kit specification, the mouse is killed after the blood taking is finished, the abdominal cavity is opened to separate the liver, the total weight of the liver is measured, the coefficient of the liver organ is calculated for statistical analysis, and the coefficient of the liver organ is × 100 percent of the weight of the liver organ.

Weighing the liver, then taking a left leaf and fixing the left leaf with formalin in the liver tissue for tissue section and HE staining, then taking two small liver tissues and weighing respectively, wherein one liver tissue is homogenized and then is used for measuring SOD, MDA, CAT, GSHPX, GST, L DH and GSH according to a kit instruction method, and the other liver tissue is weighed and then is homogenized and then is used for measuring the TG content of the liver (animal experiment groups and a drug administration scheme are shown in table 1).

The method for measuring the content of TG in liver comprises the steps of adding 10% of liver homogenate tissue 50 mu L, distilled water 50 mu L, methanol 200 mu L and chloroform 400 mu L into a 1.5m L EP tube, fully mixing, adding organic phase liquid 200 mu L into a new EP tube, volatilizing, fully dissolving by using 500 mu L isopropanol, and finally measuring the content of TG by using a kit.

TABLE 1

Statistical analysis, SPSS 22.0 is used for data statistical analysis, One-way ANOVA is used for inter-group comparison of measured data, homogeneity of variance analysis and normal distribution test are carried out before comparison, L SD test is used when the variance is uniform, and Dunnett T3 test is used when the variance is irregular.

The experimental results are as follows: (1) general condition of animal, weight and liver organ coefficient change

In the initial stage of the experiment, when 2g/kg of ethanol is used for gastric lavage of mice, all the mice do not have obvious drunkenness performance, individual mice are excited, and running movement in cages is increased. When the amount of the ethanol is increased to 4g/kg, partial mice have the symptoms of drunkenness and central nerve inhibition, and have the symptoms of unstable gait, rapid respiration, cage wall scratching, side lying and sleeping until righting reflex disappears. The above-mentioned intoxication was observed in all mice when the amount of ethanol was increased to 6g/kg, which lasted from 30 minutes to 2 hours.

In the experiment, one mouse of the medium-dose group and one mouse of the high-dose group of the test sample died from the administration of the drug for 21 and 22 days, and no significant abnormality was observed in the dissection. No animal death occurred during the experiment in the remaining 4 groups of mice. The body weight of the mice in the normal control group gradually increased during the experiment, and the body weight increased by 28.9 percent compared with the initial body weight by the end of the experiment. The weight of the mice in each group except the normal control group is slowly increased, and the weight of the mice in each group except the normal control group is reduced after the ethanol gavage dose is increased to 6g/kg for one week. By the end of the experiment, the body weight of the mice in each drug group was increased by 2.2% -3.5% of the initial body weight (fig. 1). In addition, the mice in the group of gavage with ethanol also appeared dark and untidy in hair color and were less spiritual than the mice in the normal control group.

The liver organ coefficients were determined after the experiment was completed, and the results showed that the liver organ coefficients of the mice in the model control group were increased (4.4% vs 4.1%, P ═ 0.109) compared to the normal control group, and the liver organ coefficients of the mice in each test sample group were decreased (4.2% and 4.3%) compared to the model control group, but were not statistically different (fig. 2).

(2) Changes in hematological indices in mice

The serum glutamic-pyruvic transaminase (a L T), glutamic-oxalacetic transaminase (AST), Triglyceride (TG), total Cholesterol (CHO), gamma-glutamyl transpeptidase (gamma-GT), low density lipoprotein cholesterol (L D L-c), acid phosphatase (ACP) and total bilirubin (TBI L) of the mice were assayed after the experiment was completed, and the results showed that:

① compared with the normal control group, the serum A L T and AST levels of the model control group mice are obviously increased (83.6U/L vs 53.5U/L and 235.3U/L vs 140.9U/L respectively), which indicates that the liver injury model is successful, the serum A L T of the middle and high dose group of the tested sample E is obviously reduced compared with the model group (figure 3), and the AST of the mouse serum is reduced by all three doses of the sample E (figure 4).

② in the blood lipid index, compared with the normal control group, the serum TG and L D L-c levels of the model control group mice are obviously increased, and three doses of the sample E all show TG reduction effects with different degrees, but the dose-effect relationship is not obvious (figure 5). L D L-c index, the sample E enables the serum L D L-c level of the mice to be obviously reduced and shows dose-dependent effect (figure 6), and all samples have no obvious effect on the serum CHO level (figure 7).

③ in other indexes, compared with the normal control group mice, the serum gamma-GT level of the model control group mice is obviously increased, and all the tested samples reduce the serum gamma-GT level (namely GGT level in figure 8) of the mice, but have no statistical difference (figure 8). in the experiment, the serum TBI L and ACP level of each group of mice have no obvious difference (figure 9 and figure 10).

(3) Biochemical and enzymatic changes of mouse liver tissue

After the experiment, the mouse is sacrificed, a small piece of liver is accurately weighed, 10% homogenate is prepared, different concentrations are diluted according to the requirements of a kit specification, and the liver tissues TG, SOD, MDA, CAT, GSHPX, GST, L DH and GSH are measured, and the results show that:

① hepatic TG levels were significantly higher in the model group mice compared to the normal control group (41.8mg/g liverweight vs 23.7mg/g liverweight), while all the test samples reduced hepatic TG levels to different degrees with a significant statistical difference compared to the model control group (FIG. 11).

② liver SOD and MDA compared with the normal control group, the mouse liver SOD level of the model control group is significantly reduced (305.4U/mgprotvs 396.1U/mgprot), the liver SOD level is slightly increased compared with the model group by high dose in the tested sample E, but no statistical difference exists (figure 12). compared with the normal control group, the mouse liver MDA level of the model control group is significantly increased (2.7nmol/mgprotvs 1.7nmol/mgprot), the sample E of the high dose group reduces the liver MDA level, and has statistical difference compared with the model group (figure 13).

③ GST, GSHPX, GSH and CAT in mouse of model control group are reduced significantly compared with normal control group, GST and GSHPX in mouse of sample E are increased significantly after three dosage groups are administered, wherein the low dosage group is increased significantly (FIG. 14). GSHPX in mouse of sample E is increased slightly after three dosage groups are administered, but there is no statistical difference compared with model group (FIG. 15). although GSH and CAT in mouse of model control group are reduced significantly compared with normal control group, in this experiment, only positive drug bicyclol shows increase effect of GSH and CAT, and GSH and CAT in all tested sample liver are not statistically different from model control group (FIG. 16 and FIG. 17).

④ liver L DH liver L DH levels were not significantly different between experimental groups (including model control and normal control group) (FIG. 18).

The experimental results prove that the anti-inebriation composition preparation prepared in the embodiment 1 has a protection effect on alcoholic liver injury and an auxiliary treatment effect, and the anti-inebriation composition has a good pharmacological effect, is non-toxic, safe and effective.

The experiments which are the same as the experiments in the embodiment 10 are carried out on the antialcoholic composition preparations prepared in the embodiments 2 to 9, and the antialcoholic composition preparations prepared in the embodiments 2 to 9 have the obvious protective effect and the auxiliary treatment effect on the liver of the mouse with alcoholic liver injury, have good pharmacological effect, and are safe and nontoxic.

Example 11

In this experiment, the soft capsules of the anti-hangover composition prepared in examples 1 to 9 were subjected to a human body feeding trial test, and were administered to 80 drinkers, respectively, while keeping the other conditions of each experiment the same, and the proportion of the anti-hangover effect was observed and recorded, and the results are shown in table 2.

TABLE 2

As can be seen from table 2, the results of the human body feeding trial tests show that the anti-hangover composition preparation of the present invention can promote rapid absorption and decomposition of alcohol in vivo, is beneficial to rapid anti-hangover of alcohol intake patients, and prevents hangover, and can also be added to food in a proper amount to obtain functional food, so as to protect liver.

The applicant states that the invention is described by the above examples to describe the anti-hangover composition, the anti-hangover liver-protecting preparation containing the same and the application thereof, but the invention is not limited to the above examples, i.e. the invention is not limited to the above examples. It will be apparent to those skilled in the art that any modification of the present invention, equivalent substitutions of selected materials and additions of auxiliary components, selection of specific modes and the like, which are within the scope and disclosure of the present invention, are contemplated by the present invention.

Claims

1. The hangover alleviating composition is characterized by comprising the following raw material extract components in parts by weight:

2. the anti-inebriation composition of claim 1, wherein the anti-inebriation composition is composed of the following raw material extract components in parts by weight:

3. the anti-inebriation composition of claim 2, wherein the anti-inebriation composition is composed of the following raw material extract components in parts by weight:

4. the anti-hangover composition according to claim 1, further comprising any one or a combination of at least two of 1 to 7 parts by weight of an extract of dried orange peel, 1 to 8 parts by weight of an extract of cistanche deserticola, 1 to 6 parts by weight of an extract of lycium barbarum, 1 to 5 parts by weight of an extract of dioscorea opposita, 1 to 7 parts by weight of an extract of hawthorn, 1 to 3 parts by weight of an extract of jujube, 1 to 3 parts by weight of an extract of glycyrrhiza uralensis, or 1 to 5 parts by weight of an extract of poria cocos.

5. The anti-hangover composition according to claim 1, further comprising 1 to 7 parts by weight of an extract of citrus reticulata blanco.

6. The anti-hangover composition according to claim 1, further comprising 1 to 8 parts by weight of cistanche salsa extract.

7. The anti-hangover composition according to claim 1, further comprising 1 to 6 parts by weight of an extract of lycium barbarum.

8. The anti-hangover composition according to claim 1, further comprising 1 to 5 parts by weight of yam extract.

9. The anti-hangover composition according to claim 1, further comprising 1 to 7 parts by weight of a hawthorn extract.

10. The anti-hangover composition according to claim 1, further comprising 1 to 3 parts by weight of jujube extract.

11. The anti-hangover composition according to claim 1, further comprising 1 to 3 parts by weight of a licorice extract.

12. The anti-hangover composition according to claim 1, further comprising 1 to 5 parts by weight of an extract of poria cocos wolf.

13. The anti-hangover composition according to any one of claims 1 to 12, wherein the raw material extract components are obtained by extracting the raw materials alone or by mixing the raw materials and then extracting the mixture.

14. The hangover-alleviating composition according to claim 13, wherein the mixing and extraction process comprises mixing and pulverizing the raw materials, soaking in water for 1-2h, extracting, and concentrating under reduced pressure in vacuum to obtain a concentrated solution with a density of 1.02-1.06g/m L to obtain the hangover-alleviating composition.

15. The hangover alleviating composition according to claim 13, wherein the mixing and extracting process comprises mixing and pulverizing the raw materials, soaking for 1-2h, performing ultrasonic circulation extraction, and after extraction is finished, vacuum concentrating under reduced pressure to a density of 1.02-1.06g/m L to obtain a concentrated solution, thereby obtaining the hangover alleviating composition.

16. The anti-hangover composition as claimed in claim 15, wherein the ultrasonic power during the ultrasonic circulation extraction is 300-.

17. An anti-hangover and hepatoprotective formulation comprising the anti-hangover composition of any one of claims 1 to 16.

18. The preparation of claim 17, wherein the preparation is in the form of capsule, tablet, pill, oral liquid, ointment, gel or aerosol.

19. The preparation of claim 17, wherein the anti-hangover composition is directly prepared into oral liquid, ointment, gel or aerosol.

20. The preparation of claim 17, wherein the anti-hangover composition is dried to powder and then made into capsules, tablets or pills.

21. The preparation of claim 20, wherein the drying is spray drying.

22. The preparation of claim 20, wherein the capsule is a soft capsule.

23. The preparation of claim 22, wherein the soft capsule is prepared by the following method:

24. Use of the anti-hangover composition according to any one of claims 1 to 16 in a functional food for protecting liver.